Current Drug Repurposing Strategies for Rare Neurodegenerative Disorders.

Area of Science:

• Neuroscience and Pharmacology
• Rare Disease Therapeutics

Background:

• Rare diseases are debilitating, often genetic, disorders with significant unmet needs in prevention, diagnosis, and treatment.
• High costs and low market returns deter pharmaceutical investment in novel orphan drug development.
• Existing therapeutic options for rare neurodegenerative disorders are limited.

Purpose of the Study:

• To explore the scientific, regulatory, and economic feasibility of drug repurposing for rare neurodegenerative diseases.
• To highlight the potential of repurposed drugs as a time- and cost-saving strategy.
• To focus on specific conditions: Huntington's disease, Friedreich's ataxia, Wolfram syndrome, and amyotrophic lateral sclerosis.

Main Methods:

• Review of scientific literature on drug repurposing for rare neurodegenerative disorders.
• Analysis of regulatory pathways and economic incentives for orphan drug development.
• Discussion of collaborative roles among academia, industry, and patient organizations.

Main Results:

• Drug repurposing presents a viable alternative to de novo drug discovery for rare diseases.
• Successful repurposing requires addressing scientific, regulatory, and economic challenges.
• Collaboration is crucial for identifying and evaluating candidate repurposed drugs.

Conclusions:

• Drug repurposing is a promising strategy to accelerate the development of treatments for rare neurodegenerative diseases.
• Multidisciplinary collaboration is essential for overcoming barriers in orphan drug development.
• Further research and investment are needed to fully realize the potential of repurposed therapies.